ALUR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Allurion Technologies Inc (ALUR) is not a good buy for a beginner, long-term investor at this time. The stock is showing bearish technical indicators, weak financial performance, and lacks strong positive catalysts despite the recent FDA approval. The company's financials indicate significant declines in revenue, net income, and EPS, which are critical for long-term investment. While the FDA approval is a positive development, it does not outweigh the current financial and technical weaknesses.
The technical indicators for ALUR are bearish. The MACD is negatively expanding below zero, the RSI is neutral at 30.657, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 0.723, but there is no clear signal for a reversal or upward momentum.
The FDA approval for Allurion's gastric balloon system is a positive development, potentially expanding the company's market opportunities. Additionally, an analyst upgrade with a $3 price target reflects optimism about the company's future prospects.
The company's financial performance in Q3 2025 is significantly weak, with revenue down 50.48% YoY, net income down 236.03% YoY, and EPS down 145.00% YoY. Gross margin also declined by 15.37%. Technical indicators are bearish, and there is no recent congress trading data or significant insider/hedge fund activity to support a buy decision.
In Q3 2025, Allurion Technologies reported a revenue decline of 50.48% YoY to $2,658,000. Net income dropped by 236.03% YoY to -$11,884,000, and EPS fell by 145.00% YoY to -1.53. Gross margin also declined to 49.06%, down 15.37% YoY. These figures indicate significant financial struggles.
Chardan analyst Keay Nakae upgraded the stock to Buy from Neutral with a $3 price target, citing the FDA approval for the gastric balloon system as a significant positive development. However, this optimism is not yet reflected in the stock's performance or financials.
